Avalon BioVentures — 2025 Investments
2 investments dated 2025 · listed companies and verified rows first · show all
Enlaza Therapeutics develops covalent protein therapeutics using its War-Lock technology, which incorporates proprietary unnatural amino acids into protein drugs so they form irreversible covalent bonds with disease-related targets.
BiotechDeep TechSan Diego, US
Sergio Duron(Co-Founder & Chief Executive Officer)Sanford Madigan(Co-Founder, President & Chief Business Officer)Analeah Heidt(Chief Scientific Officer)
Board seatJay B. Lichter· per SEC Form D
HealthtechLa Jolla, US
Ahmet Tutuncu, M.D., Ph.D.(Executive Officer, Director)
BoardTighe Reardon(Executive Officer)Heather Preston, M.D.(Director)Jay B. Lichter, Ph.D.(Director)Sanford Madigan, Ph.D.(Director)John Stuart Patton, Ph.D.(Director)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.